CORT-X (NCT04601038) is a Phase 2 clinical trial evaluating CORT108297, a selective glucocorticoid receptor antagonist, for stress attenuation in patients with mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and cognitively normal individuals with AD risk factors. The trial is conducted by Johns Hopkins University and is currently recruiting[1].
This trial represents a paradigm shift in AD therapeutic development by targeting the stress-neurodegeneration axis rather than the traditional amyloid or tau pathways. Given the well-established link between chronic stress, elevated cortisol, and cognitive decline, this approach offers a novel disease-modifying strategy that could complement existing treatments.
The relationship between chronic stress and neurodegenerative disease has been extensively documented over the past three decades. The landmark study by Lupien and colleagues demonstrated that elevated cortisol levels during aging predict hippocampal atrophy and memory deficits, establishing a causal link between glucocorticoid exposure and cognitive decline[2].
Hippocampal Vulnerability
The hippocampus is particularly vulnerable to glucocorticoid toxicity for several reasons:
Mechanisms of Damage
Chronic glucocorticoid exposure leads to:
The cortisol-tau pathway describes how stress hormones promote Alzheimer's disease progression:
This pathway provides a mechanistic link between psychological stress and the core AD pathological cascade.
The glucocorticoid receptor (GR) is a ligand-activated transcription factor that mediates the genomic effects of cortisol. Understanding its biology is essential for appreciating CORT108297's mechanism of action.
Receptor Types
| Receptor | Affinity | Distribution | Function |
|---|---|---|---|
| Mineralocorticoid (MR) | High (corticosterone) | Hippocampus, amygdala | Stress response initiation |
| Glucocorticoid (GR) | Low (corticosterone) | Ubiquitous | Negative feedback, stress termination |
GR Signaling Pathways
CORT108297 is a selective glucocorticoid receptor antagonist designed to block the adverse effects of cortisol on the brain while preserving its essential functions.
Chemical Characteristics
Mechanism of Action
CORT108297 acts by:
Therapeutic Benefits
By antagonizing GR, CORT108297 may:
The CORT-X trial employs a rigorous randomized, double-blind, placebo-controlled design:
| Parameter | Value |
|---|---|
| NCT Number | NCT04601038 |
| Official Title | Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X) |
| Acronym | CORT-X |
| Phase | Phase 2 |
| Status | RECRUITING |
| Design | Randomized, parallel-group, double-blind, controlled |
| Sponsor | Johns Hopkins University |
| Duration | 2 weeks treatment |
| Arm | Type | Intervention | Dose |
|---|---|---|---|
| CORT108297 | Active Comparator | 120mg selective glucocorticoid receptor antagonist | 2 tablets daily for 2 weeks |
| Placebo | Placebo Comparator | Matching placebo | 2 tablets daily for 2 weeks |
Inclusion Criteria
Cognitive Status (Either):
Exclusion Criteria
The trial uses cognitive assessments specifically sensitive to stress effects on memory systems:
| Assessment | Domain | Relevance |
|---|---|---|
| Pattern Separation Task | Memory discrimination | Hippocampal function |
| Hopkins Verbal Learning Test-Revised (HVLT-R) | Verbal memory | Allocortex integrity |
| Trail Making Test Part B | Executive function | Frontal connectivity |
| Digit Span Task (backwards) | Working memory | Attention systems |
| Visit | Timing | Assessments |
|---|---|---|
| Screening | -4 to -2 weeks | Medical history, cognitive testing, MRI eligibility |
| Baseline | Day 0 | Randomization, cognitive testing, stress challenge |
| Treatment | Days 1-14 | Daily dosing, symptom monitoring |
| End of Treatment | Day 14-15 | Cognitive testing, biomarker sampling |
| Follow-up | Day 28 | Safety assessment |
A unique feature of this trial is the acute stress challenge:
This trial addresses a critical gap in AD therapeutics by targeting a fundamental pathway not addressed by current treatments:
Novel Mechanism
Disease Modification Potential
Preventive Approach
Complementary Strategy
The development of CORT108297 for AD is supported by substantial preclinical data:
Animal Models
Human Data
Epidemiological and clinical studies support the stress-AD connection:
Elevated Cortisol in AD
Stress as Risk Factor
Cortisol-Tau Relationship
CORT108297 represents a unique approach in the AD therapeutic landscape:
| Approach | Target | Status | Mechanism |
|---|---|---|---|
| CORT108297 | Glucocorticoid receptor | Phase 2 | Stress pathway modulation |
| Lecanemab | Amyloid-β | Approved | Amyloid clearance |
| Donanemab | Amyloid-β | Approved | Amyloid clearance |
| LY-3372689 | O-GlcNAcase | Completed | Tau O-GlcNAcylation |
| Davunetide | Microtubule stabilization | Failed | Neuroprotection |
Understanding glucocorticoid receptor signaling is essential for appreciating CORT108297's potential benefits and limitations.
Genomic Mechanisms
Transactivation (GR-GRE)
Transrepression (GR-NF-κB)
Negative Feedback
Non-Genomic Mechanisms
Membrane Effects
Cytoplasmic Effects
CORT108297's potential benefits in AD derive from blocking GR-mediated stress effects:
Tau Phosphorylation
Synaptic Plasticity
Neuronal Survival
Neuroinflammation
A positive result would:
A negative result would:
For AD Treatment
For Neuroscience
Based on other GR antagonists (e.g., mifepristone):
Common Adverse Effects
Specific Considerations
The 2-week treatment duration is designed to:
Future trials may benefit from:
Alternative approaches to GR modulation:
The CORT-X trial represents an innovative approach to Alzheimer's disease treatment by targeting the stress-neurodegeneration axis through glucocorticoid receptor antagonism. This strategy addresses a fundamental pathway not covered by current therapies, potentially providing disease modification through a novel mechanism.
Key Points
The successful development of CORT108297 would represent a paradigm shift in AD therapeutics, validating stress pathway targeting and opening new avenues for disease modification.
The glucocorticoid receptor regulates gene expression through multiple mechanisms:
Transactivation Pathway
The classical GR signaling pathway involves:
Transrepression Pathway
The transrepression mechanism provides anti-inflammatory effects without classic GRE binding:
Gene Targets
| Gene Category | Expression Change | Effect |
|---|---|---|
| IκBα | Increased | NF-κB inhibition |
| Annexin-1 | Increased | Anti-inflammatory |
| IL-10 | Increased | Anti-inflammatory cytokine |
| MMP-9 | Decreased | Reduced inflammation |
| COX-2 | Decreased | Reduced prostaglandins |
Rodent Models of Stress-Induced Neurodegeneration
Multiple preclinical models support GR antagonism in AD:
Chronic Corticosterone Administration Model
| Parameter | Effect | AD Relevance |
|---|---|---|
| Hippocampal volume | Reduced | Atrophy modeling |
| Memory performance | Impaired | Cognitive deficit |
| Tau phosphorylation | Increased | NFT precursor |
| Synaptic markers | Reduced | Synaptopathy |
| Neurogenesis | Decreased | Adult neurogenesis loss |
Chronic Stress Model
| Behavioral Change | Molecular Finding | Interpretation |
|---|---|---|
| Impaired memory | Reduced BDNF | Synaptic dysfunction |
| Anhedonia | Altered 5-HT | Mood effects |
| Hyperarousal | HPA axis dysregulation | Feedback failure |
| Reduced exploration | Neuronal atrophy | Structural change |
Pharmacological Evidence
| Compound | Model | Outcome | Relevance to CORT108297 |
|---|---|---|---|
| Mifepristone | Corticosterone-treated mice | Improved memory | Proof-of-concept |
| RU-486 | Chronic stress model | Reduced tau phosphorylation | Mechanism validation |
| CORT108297 | Pilot studies | BBB penetration | Development rationale |
| GR-ASO | Knockdown models | Protection | Target validation |
Biomarker Categories
The trial includes multiple biomarker endpoints:
| Biomarker | Sample | Pathway | Clinical Correlation |
|---|---|---|---|
| Cortisol (basal) | Serum | HPA axis activity | Disease severity |
| Cortisol (stressed) | Serum | Stress response | Treatment effect |
| DHEA | Serum | Neurosteroid balance | Antagonistic effect |
| IL-6 | Serum | Inflammation | Inflammation level |
| BDNF | Serum/CSF | Neurotrophin | Synaptic health |
| Tau | CSF | Pathology | AD progression |
Stress Challenge Response
A unique aspect of the CORT-X trial is the acute stress challenge:
Interpretation of Stress Challenge Results
| Response Pattern | Baseline | Post-Treatment | Interpretation |
|---|---|---|---|
| Normal | Peak +50% | Peak +50% | No effect |
| Blunted | Peak +30% | Peak +45% | Partial blockade |
| Blocked | Peak +20% | Peak +20% | Full blockade |
Alternative GR Modulators
| Compound | GR Activity | Development Stage | Advantages |
|---|---|---|---|
| CORT108297 | Antagonist | Phase 2 | Brain-penetrant |
| Mifepristone | Antagonist | Approved (Cushing's) | Approved, well-characterized |
| Relacarsen | Partial agonist | Preclinical | Tissue-selective |
| Compound A | Selective modulator | Research | Novel mechanism |
GR Agonists vs Antagonists in AD
| Approach | Mechanism | Rationale | Risk |
|---|---|---|---|
| GR agonists | Transactivation | Neuroprotection | Immunosuppression |
| GR antagonists | Transrepression | Anti-inflammatory | HPA axis disruption |
| SGRMs | Balanced | Selective | Safety window |
Acute Stress Challenge Methodology
The stress challenge uses standardized procedures:
| Component | Protocol | Measurement |
|---|---|---|
| Task | Trier Social Stress Test | Public speaking + math |
| Duration | 15 minutes | Standardized |
| Cortisol sampling | 0, 15, 30, 60 min | Time points |
| Cognitive testing | Post-stress | Immediate |
Cognitive Endpoint Selection
| Test | Construct | Stress Sensitivity | Rationale |
|---|---|---|---|
| Pattern Separation | Memory discrimination | High | Hippocampal-specific |
| HVLT-R | Verbal memory | Moderate | Standard AD trial |
| Trail Making B | Executive function | Moderate | Frontal connectivity |
| Digit Span | Working memory | Moderate | Attention |
Statistical Analysis Plan
| Endpoint | Analysis | Power | Assumptions |
|---|---|---|---|
| Primary cognitive | ANCOVA | 80% | d=0.5 |
| Stress response | Paired t-test | 90% | 40% reduction |
| Biomarker | Mixed model | 80% | Time x treatment |
Dose Optimization Study
| Parameter | Phase 2 | Phase 2b | Phase 3 |
|---|---|---|---|
| Dose | 120mg fixed | Multiple doses | Optimal dose |
| Duration | 2 weeks | 4-8 weeks | 6-12 months |
| N | 60 | 200 | 800 |
| Design | Placebo-controlled | Dose-finding | Pivotal |
Long-Term Extension
Key questions for long-term studies:
Rationale for Combinations
CORT108297 may synergize with:
| Combination | Rationale | Timeline |
|---|---|---|
| + Lecanemab | Complementary mechanisms | Phase 3+ |
| + Donanemab | Tau + stress pathways | Phase 3 |
| + Vitamin D | Synergistic neuroprotection | Phase 2 |
| + Exercise | Enhanced neurogenesis | Phase 2 |
Patient Selection
Future development may incorporate:
| Biomarker | Use | Status |
|---|---|---|
| Baseline cortisol | Enrichment | Retrospective |
| GR genotype | Safety | Research |
| Stress reactivity | Response prediction | Development |
| Hippocampal volume | Prognosis | Validated |
Personalized Approach
The ultimate goal is personalized treatment selection:
Development Program Elements
| Designation | Status | Benefit |
|---|---|---|
| Fast Track | Eligible | Accelerated approval |
| Breakthrough | Potential | Intensive guidance |
| Orphan | Not applicable | N/A |
| Priority Review | Future | Faster review |
Approval Pathway
Based on the mechanism and patient population:
Phase II Trial of CORT108297 to Attenuate the Effects of Acute Stress in the Allocortex (CORT-X). ↩︎
Lupien SJ, et al. Cortisol levels during human aging predict hippocampal atrophy and memory deficits. Nature Neuroscience. 1998. ↩︎